Related Experiment Videos
The Case Against Prophylactic Cranial Irradiation in Limited Small Cell Lung Cancer
1Department of Medicine, Indiana University, Indianapolis, IN, USA
Seminars in Radiation Oncology
|January 1, 1995
Summary
Advances in small cell lung cancer treatment improve survival, but cures remain rare. Prophylactic cranial irradiation
Area of Science:
- Oncology
- Pulmonology
- Radiotherapy
Background:
- Small cell lung cancer (SCLC) treatment has advanced significantly over the last 20 years.
- Systemic chemotherapy and combined modality therapy have improved survival rates for both extensive and limited SCLC.
- Despite improvements, cures are rare in extensive disease, while limited disease shows a 5-year survival of approximately 20%.
Purpose of the Study:
- To review current data on prophylactic cranial irradiation (PCI) in small cell lung cancer.
- To evaluate the benefits and toxicity associated with PCI.
- To analyze results from randomized clinical trials investigating PCI in SCLC patients.
Main Methods:
- Review of existing literature and randomized clinical trials.
- Analysis of data concerning the efficacy of PCI.
- Assessment of treatment-related toxicity and patient outcomes.
Main Results:
- Chemotherapy improves median survival in extensive SCLC but rarely leads to cure.
- Limited SCLC patients achieving complete remission have a 5-year survival rate of about 20%.
- Controversy exists regarding the role of PCI, particularly in limited SCLC patients with complete remission.
Conclusions:
- PCI remains a topic of significant debate in SCLC management.
- Further analysis of randomized trials is crucial to define the role of PCI.
- Balancing potential benefits against toxicity is key for optimal SCLC treatment strategies.